Bay Biosciences provides high quality, clinical grade bio-samples, cryogenically preserved primary PD-L1 positive and secondary metastatic tumor tissue samples with matched serum (sera), plasma and peripheral blood mononuclear cells (PBMC) biofluid specimens from patients diagnosed with metastatic triple-negative breast cancer (TNBC).
The PBMC, serum (sera) and plasma samples are processed from patient’s peripheral whole-blood using customized processing protocols provided by the customer. The metastatic triple-negative breast cancer bio-specimens are collected from unique patients diagnosed with stage IV distant metastatic (liver) triple-negative breast cancer and are provided to a valued pharmaceutical customer for research, development and discovery.
Triple-Negative Breast Cancer (TNBC) Overview
Triple-negative breast cancer (TNBC) is a cancer that tests negative for estrogen receptors (ER), progesterone receptors (PR), and excess HER2 protein. These results mean the growth of the cancer is not fueled by the hormones estrogen and progesterone, or by the HER2 protein. So, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2 protein receptors.
About 10-20% of breast cancers are triple-negative breast cancers. For researchers, there is intense interest in discovering new medications that can treat TNBC breast cancer. Studies are investigating whether certain medications can interfere with the processes that cause triple-negative breast cancer to grow. Triple-negative breast cancer (TNBC) tend to be more common in women younger than age 40 or who have a BRCA1 mutation. Triple-negative breast cancer differs from other types of invasive breast cancer in that they grow and spread faster, have limited treatment options, and a worse prognosis (outcome).
About 10-20% of breast cancers which test negative for both hormone receptors (ER & PR negative) and excess HER2 (negative), are triple-negative. Since hormones aren’t fueling the cancer growth, the cancer is unlikely to respond to hormonal therapy medicines, including tamoxifen and aromatase inhibitors. Triple-negative breast cancer also is unlikely to respond to medicines that target the HER2 protein, such as Enhertu, Herceptin (trastuzumab), Kadcyla (T-DMA), Nerlynx (neratinib), Perjeta (pertuzumab), or Tykerb (lapatinib).
Triple-Negative Breast Cancer (TNBC) Features
- Triple-negative breast cancer (TNBC) is considered to be more aggressive and have a poorer prognosis than other types of breast cancer, mainly because there are fewer targeted medicines that treat triple-negative breast cancer. Studies have shown that triple-negative breast cancer is more likely to spread (metastasize) beyond the breast into other distant organs and more likely to recur (come back) after treatment.
- Triple-negative breast cancer (TNBC) tends to be higher grade than other types of breast cancers. The higher the grade, the less the cancer cells resemble normal, healthy breast cells in their appearance and growth patterns. On a scale of 1 to 3, triple-negative breast cancer often is grade 3.
- Triple-negative breast cancer (TNBC) usually is a cell type called Basal-like which means that the cells resemble the basal cells that line the breast ducts. Basal-like cancers tend to be more aggressive, higher grade cancers, just like triple-negative breast cancers. Most but not all basal-like breast cancers are triple negative, and most but not all triple-negative breast cancers are basal-like.
Triple-Negative Breast Cancer (TNBC) Signs & Symptoms
Triple-negative breast cancer (TNBC) have the same sign and symptoms as other common types of breast cancer. The most common symptom of breast cancer is a new lump or mass. A painless, hard mass that has irregular edges is more likely to be cancer, but breast cancers can be tender, soft, or round. They can even be painful. For this reason, it’s important to have any new breast mass, lump, or breast change checked by an experienced health care professional.
Other Symptoms of Breast Cancer include:
- Swelling of all or part of a breast (even if no lump is felt)
- Skin dimpling (sometimes looking like an orange peel)
- Breast or nipple pain
- Nipple retraction (turning inward)
- Nipple or breast skin that is red, dry, flaking or thickened
- Nipple discharge (other than breast milk)
- Swollen lymph nodes (Sometimes a breast cancer can spread to lymph nodes under the arm or around the collar bone and cause a lump or swelling there, even before the original tumor in the breast is large enough to be felt.)
Triple-Negative Breast Cancer (TNBC) Treatment
Triple-negative breast cancer (TNBC) has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the human epidermal growth factor receptor2 (HER2) protein to make hormone therapy or targeted drugs work.
If the cancer has not spread to distant sites, surgery is an option. Chemotherapy might be given first to shrink a large tumor followed by surgery. It might also be given after surgery to reduce the chances of the cancer coming back. Radiation might also be an option depending on certain features of the tumor. Because hormone therapy and HER2 drugs are not choices for women with triple negative breast cancer, chemotherapy is often used. In cases where the cancer has spread to other parts of the body (stage IV) chemotherapy and other treatments that can be considered include PARP inhibitors, platinum chemotherapy, or immunotherapy.
Detailed clinical data, ER, PR, HER2 negative pathology reports, breast MRI scans, elevated biomarker levels, PD-L1, BRCA, genetic & metabolic information, histopathological findings, annotations associated with the metastatic triple-negative breast cancer patient’s specimens are provided to a valued customer for drug discover, development and research. The metastatic triple-negative breast cancer serum (sera), plasma and PBMC samples are processed from patients peripheral whole-blood using customized processing protocols provided by the researcher.
Bay Biosciences is a global leader in providing researchers with high quality, clinical grade, fully characterized human tissue samples, bio-specimens and human bio-fluid collections from cancer (tumor) tissue, cancer serum, cancer plasma cancer PBMC and human tissue samples from most other therapeutic areas and diseases.
Bay Biosciences maintains and manages it’s own bio-repository, human tissue bank (biobank) consisting of thousands of diseased samples (specimens) and from normal healthy donors available in all formats and types. Our biobank procures and stores fully consented, deidentified and institutional review boards (IRB) approved human tissue samples and matched controls.
All our human human tissue collections, human specimens and human bio-fluids are provided with detailed samples associated patient’s clinical data. This critical patient’s clinical data includes information relating to their past and current disease, treatment history, lifestyle choices, biomarkers and genetic information. Patient’s data is extremely valuable for researchers and is used to help identify new effective treatments (drug discovery & development) in oncology, other therapeutic areas and diseases. This clinical information is critical to demonstrate their impact, monitor the safety of medicines, testing & diagnostics, and generate new knowledge about the causes of disease and illness.
Bay Biosciences banks wide variety of human tissue samples and biological samples including cryogenically preserved -80°C, fresh, fresh frozen tissue samples, tumor tissue samples, FFPE’s, tissue slides, with matching human bio-fluids, whole blood and blood derived products such as serum, plasma and PBMC’s.
Bay Biosciences is a global leader in collecting and providing human tissue samples according to the researchers specified requirements and customized, tailor made collection protocols. Please contact us anytime to discuss your special research projects and customized human tissue sample requirements.
Bay Biosciences provides human tissue samples (human specimens) from diseased and normal healthy donors; including peripheral whole-blood, amniotic fluid, bronchoalveolar lavage fluid (BAL), sputum, pleural effusion, cerebrospinal fluid (CSF), serum (sera), plasma, peripheral blood mononuclear cells (PBMC’s), saliva, Buffy coat, urine, stool samples, aqueous humor, vitreous humor, kidney stones, renal calculi, nephrolithiasis, urolithiasis and other bodily fluids from most diseases including cancer. We can also procure most human bio-specimens and can do special collections and requests of human samples that are difficult to find. All our human tissue samples are procured through IRB approved clinical protocols and procedures.
In addition to the standard processing protocols Bay Biosciences can also provide human plasma, serum, PBMC bio-fluid samples using custom processing protocols, you can buy donor specific sample collections in higher volumes and specified sample aliquoting from us. Bay Biosciences also provides human samples from normal healthy donors, volunteers, for controls and clinical research, contact us Now.
日本のお客様は、ベイバイオサイエンスジャパンBay Biosciences Japanまたはhttp://baybiosciences-jp.com/contact/までご連絡ください。